BR112021022363A2 - Composições e métodos para fabricação de células t - Google Patents
Composições e métodos para fabricação de células tInfo
- Publication number
- BR112021022363A2 BR112021022363A2 BR112021022363A BR112021022363A BR112021022363A2 BR 112021022363 A2 BR112021022363 A2 BR 112021022363A2 BR 112021022363 A BR112021022363 A BR 112021022363A BR 112021022363 A BR112021022363 A BR 112021022363A BR 112021022363 A2 BR112021022363 A2 BR 112021022363A2
- Authority
- BR
- Brazil
- Prior art keywords
- cells
- manufacturing
- compositions
- methods
- specific
- Prior art date
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title abstract 3
- 238000004519 manufacturing process Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 238000002659 cell therapy Methods 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000006698 induction Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464401—Neoantigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46449—Melanoma antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0081—Purging biological preparations of unwanted cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0081—Purging biological preparations of unwanted cells
- C12N5/0087—Purging against subsets of blood cells, e.g. purging alloreactive T cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/876—Skin, melanoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/57—Skin; melanoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Moulding By Coating Moulds (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Casting Or Compression Moulding Of Plastics Or The Like (AREA)
Abstract
composições e métodos de fabricação de células t. a geração de células t específicas de antígeno por indução ou expansão ex vivo controlada pode proporcionar terapias de células t altamente específicas e benéficas. a presente descrição proporciona métodos de fabricação de células t e composições terapêuticas de células t que podem ser usadas para o tratamento de indivíduos com câncer e outras condições, doenças e distúrbios de terapia de células t específicas de antígenos pessoais.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962845251P | 2019-05-08 | 2019-05-08 | |
PCT/US2020/031898 WO2020227546A1 (en) | 2019-05-08 | 2020-05-07 | T cell manufacturing compositions and methods |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112021022363A2 true BR112021022363A2 (pt) | 2022-03-22 |
Family
ID=73051205
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112021022363A BR112021022363A2 (pt) | 2019-05-08 | 2020-05-07 | Composições e métodos para fabricação de células t |
Country Status (14)
Country | Link |
---|---|
US (1) | US20220280621A1 (pt) |
EP (1) | EP3965784A4 (pt) |
JP (2) | JP2022531474A (pt) |
KR (1) | KR20220044242A (pt) |
CN (1) | CN114096261A (pt) |
AR (1) | AR118859A1 (pt) |
AU (1) | AU2020268397A1 (pt) |
BR (1) | BR112021022363A2 (pt) |
CA (1) | CA3137037A1 (pt) |
IL (1) | IL287874A (pt) |
MX (1) | MX2021013608A (pt) |
SG (1) | SG11202112346WA (pt) |
TW (2) | TWI777160B (pt) |
WO (1) | WO2020227546A1 (pt) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201121308D0 (en) | 2011-12-12 | 2012-01-25 | Cell Medica Ltd | Process |
ES2748652T3 (es) | 2012-02-09 | 2020-03-17 | Baylor College Medicine | Mezclas pep para generar CTL multivíricos con amplia especificidad |
JP6999941B2 (ja) | 2015-09-18 | 2022-02-10 | ベイラー カレッジ オブ メディスン | 病原体からの免疫原性抗原同定および臨床的有効性との相関 |
US11948694B2 (en) * | 2021-05-12 | 2024-04-02 | Merative Us L.P. | Controlling compartmental flows in epidemiological modeling based on mobility data |
CA3234993A1 (en) * | 2021-10-15 | 2023-04-20 | Marit M. VAN BUUREN | T cell manufacturing compositions and methods |
WO2023159088A1 (en) * | 2022-02-15 | 2023-08-24 | Marker Therapeutics, Inc. | Compositions and methods for antigen-specific t cell expansion |
CN117417886B (zh) * | 2023-10-20 | 2024-05-14 | 广东壹加再生医学研究院有限公司 | 一种负载肿瘤抗原的树突状细胞激活的t淋巴细胞的培养方法 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2004275871A1 (en) * | 2003-09-25 | 2005-04-07 | Zymogenetics, Inc. | Methods of treating autoimmune diseases using IL-21 |
US20060286089A1 (en) * | 2005-04-08 | 2006-12-21 | Xcyte Therapies, Inc. | Compositions and methods for the treatment of burns and sepsis |
DE102005046490A1 (de) * | 2005-09-28 | 2007-03-29 | Johannes-Gutenberg-Universität Mainz | Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen |
WO2009045308A2 (en) * | 2007-10-03 | 2009-04-09 | Fred Hutchinson Cancer Research Center | Enhanced generation of cytotoxic t-lymphocytes by il-21 mediated foxp3 suppression |
JP5577472B2 (ja) * | 2012-02-10 | 2014-08-20 | 医療法人社団博心厚生会 | 単球増殖剤、単球増殖用培地、単球の製造方法、樹状細胞の製造方法、及び樹状細胞ワクチンの製造方法 |
EP3335725B1 (en) * | 2015-08-10 | 2024-02-28 | Toray Industries, Inc. | Pds5a epitopes as immunity inducers |
JP2018526034A (ja) * | 2015-09-10 | 2018-09-13 | アフィジェン・インコーポレイテッド | 腫瘍治療薬の配列決定により導かれる選択 |
CN108473956B (zh) * | 2015-10-09 | 2022-04-05 | 北昊干细胞与再生医学研究院有限公司 | 增强外源性施用t细胞的体内持久性和功效的方法、基因修饰的t细胞和方法以及使用方法 |
US20190119639A1 (en) * | 2017-09-20 | 2019-04-25 | Nexlmmune, Inc. | Cell compositions comprising antigen-specific t cells for adoptive therapy |
CA3081840A1 (en) * | 2017-11-08 | 2019-05-16 | Neon Therapeutics, Inc. | T cell manufacturing compositions and methods |
-
2020
- 2020-05-05 AR ARP200101269A patent/AR118859A1/es unknown
- 2020-05-05 TW TW109114957A patent/TWI777160B/zh active
- 2020-05-05 TW TW111130596A patent/TW202248419A/zh unknown
- 2020-05-07 JP JP2021566008A patent/JP2022531474A/ja active Pending
- 2020-05-07 CN CN202080050310.8A patent/CN114096261A/zh active Pending
- 2020-05-07 MX MX2021013608A patent/MX2021013608A/es unknown
- 2020-05-07 EP EP20801696.4A patent/EP3965784A4/en active Pending
- 2020-05-07 KR KR1020217040167A patent/KR20220044242A/ko not_active Application Discontinuation
- 2020-05-07 US US17/609,705 patent/US20220280621A1/en active Pending
- 2020-05-07 CA CA3137037A patent/CA3137037A1/en active Pending
- 2020-05-07 SG SG11202112346WA patent/SG11202112346WA/en unknown
- 2020-05-07 BR BR112021022363A patent/BR112021022363A2/pt unknown
- 2020-05-07 AU AU2020268397A patent/AU2020268397A1/en active Pending
- 2020-05-07 WO PCT/US2020/031898 patent/WO2020227546A1/en unknown
-
2021
- 2021-11-07 IL IL287874A patent/IL287874A/en unknown
-
2024
- 2024-01-29 JP JP2024011014A patent/JP2024038503A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
TW202248419A (zh) | 2022-12-16 |
AR118859A1 (es) | 2021-11-03 |
IL287874A (en) | 2022-01-01 |
JP2022531474A (ja) | 2022-07-06 |
TWI777160B (zh) | 2022-09-11 |
TW202108761A (zh) | 2021-03-01 |
EP3965784A1 (en) | 2022-03-16 |
WO2020227546A1 (en) | 2020-11-12 |
KR20220044242A (ko) | 2022-04-07 |
EP3965784A4 (en) | 2023-06-21 |
JP2024038503A (ja) | 2024-03-19 |
SG11202112346WA (en) | 2021-12-30 |
CA3137037A1 (en) | 2020-11-12 |
AU2020268397A1 (en) | 2022-01-06 |
CN114096261A (zh) | 2022-02-25 |
MX2021013608A (es) | 2022-01-31 |
US20220280621A1 (en) | 2022-09-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112021022363A2 (pt) | Composições e métodos para fabricação de células t | |
WO2019094642A8 (en) | T cell manufacturing compositions and methods | |
BR112019018863A8 (pt) | Tcrs de alta afinidade específicos para mage-a1 e usos dos mesmos | |
MX2020004948A (es) | Receptor de antígeno quimérico que selecciona como diana bcma, receptor de antígeno quimérico que selecciona como diana cd19 y terapias de combinación. | |
MX2020009773A (es) | Terapia de combinacion. | |
GT201200318A (es) | Anticuerpos hacia gdf8 humano | |
CO7350624A2 (es) | Inhibidores de la tirosina-quinasa de bruton | |
BR112022016382A2 (pt) | Triptaminas específicas para o uso no tratamento de doenças do humor | |
BR112018007656A2 (pt) | terapia de combinação para tratamento de doenças malignas | |
DOP2007000015A (es) | Usos terapéuticos de inhibidores de rtp801 | |
UY30525A1 (es) | Agentes de union dirigidos cuyo blanco es el pdgfr-alfa y sus usos | |
MX2017006938A (es) | Terapia de combinacion para el tratamiento de cancer. | |
MX2020008680A (es) | Terapia de combinacion con apilimod y agentes glutamatergicos. | |
AR109707A1 (es) | Generación y uso en inmunoterapia adoptiva de células t de memoria tipo células madre | |
CY1123501T1 (el) | Χρηση ρεσλιζουμαμπης για τη θεραπευτικη αντιμετωπιση μετριου εως σοβαρου ηωσινοφιλικου ασθματος | |
MX2019012465A (es) | Terapia combinada con un conjugado de anticuerpo y farmaco anti-cd25. | |
MX2019003134A (es) | Terapia de combinacion. | |
BR112018007671A2 (pt) | terapia de combinação para tratamento de malignidades | |
BR112015026247A2 (pt) | métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor | |
BR112022001148A2 (pt) | Células imunes modificadas, composição farmacêutica, kit, uso de uma célula imune modificada e invenção de produto | |
BR112023005160A2 (pt) | Terapia de combinação para o tratamento de câncer | |
BR112019022901A2 (pt) | precursor de linhagem mesenquimal ou células t com imunossupressão intensificada | |
EP4345110A3 (en) | Methods for treating severe atopic dermatitis by administering an il-4r inhibitor | |
BR112015031950A2 (pt) | métodos para tratamento de câncer de ovário | |
CO2023002953A2 (es) | Métodos y composiciones de fabricación de células t |